Kaposi's Sarcoma Associated with Previous Human Herpesvirus 8 Infection in Kidney Transplant Recipients

Cattani, Paola; Capuano, M.; Graffeo, Rosalia; Ricci, R.; Cerimele, Francesca; Cerimele, D; Nanni, Giuseppe; Fadda, Giovanni

doi:10.1128/jcm.39.2.506-508.2001

Cited by 96 publications

(66 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Other studies have demonstrated that KS occurred rarely after bone marrow transplantation (21); only one case of KS, possibly transmitted by the donor, has been reported in a French cohort (20). In contrast, several studies of HHV-8 infection and KS have been reported after renal transplantation (10,11,16,22,27; Frances et al, letter). In two studies from different geographic areas (Switzerland and United States), HHV-8 seroprevalence increased from 5 to 6% before to 16 to 18% within the year after renal transplantation (22,27).…”

Section: Vol 42 2004 Serological Methods For Detection Of Hhv-8 Antmentioning

confidence: 93%

“…In two studies from different geographic areas (Switzerland and United States), HHV-8 seroprevalence increased from 5 to 6% before to 16 to 18% within the year after renal transplantation (22,27). Notably, KS is clearly more prevalent in the renal transplant population, approaching 4% of transplants (10,11), indicating that the pathogenesis of HHV-8 infection in the two transplant populations is different, which may be related in part to the shorter period of immunosuppression in SCT recipients.…”

Section: Vol 42 2004 Serological Methods For Detection Of Hhv-8 Antmentioning

confidence: 99%

See 1 more Smart Citation

Comparative Evaluation of Three Serological Methods for Detection of Human Herpesvirus 8-Specific Antibodies in Canadian Allogeneic Stem Cell Transplant Recipients

et al. 2004

View full text Add to dashboard Cite

show abstract

Section: Vol 42 2004 Serological Methods For Detection Of Hhv-8 Antmentioning

confidence: 93%

Section: Vol 42 2004 Serological Methods For Detection Of Hhv-8 Antmentioning

confidence: 99%

Comparative Evaluation of Three Serological Methods for Detection of Human Herpesvirus 8-Specific Antibodies in Canadian Allogeneic Stem Cell Transplant Recipients

et al. 2004

View full text Add to dashboard Cite

show abstract

“…One study demonstrated that 10 (91%) of 11 kidney or heart transplant patients who developed iatrogenic KS were KSHV positive prior to their procedures (390). Cattani et al calculated a relative risk of 34.4 for kidney recipients who were KSHV seropositive versus seronegative prior to transplant (76). In a transplant cohort in Paris, 8% of 400 kidney transplant recipients were KSHV positive prior to transplantation: 28% of these developed KS within 3 years of their procedures, but none of those who were seronegative prior to receiving the kidney developed KS (165).…”

Section: Iatrogenic Ksmentioning

confidence: 99%

Molecular Genetics of Kaposi's Sarcoma-Associated Herpesvirus (Human Herpesvirus 8) Epidemiology and Pathogenesis

Dourmishev

Palmeri

et al. 2003

Microbiol Mol Biol Rev

309

367

View full text Add to dashboard Cite

Kaposi's sarcoma had been recognized as unique human cancer for a century before it manifested as an AIDS-defining illness with a suspected infectious etiology. The discovery of Kaposi's sarcoma-associated herpesvirus (KSHV), also known as human herpesvirus-8, in 1994 by using representational difference analysis, a subtractive method previously employed for cloning differences in human genomic DNA, was a fitting harbinger for the powerful bioinformatic approaches since employed to understand its pathogenesis in KS. Indeed, the discovery of KSHV was rapidly followed by publication of its complete sequence, which revealed that the virus had coopted a wide armamentarium of human genes; in the short time since then, the functions of many of these viral gene variants in cell growth control, signaling apoptosis, angiogenesis, and immunomodulation have been characterized. This critical literature review explores the pathogenic potential of these genes within the framework of current knowledge of the basic herpesvirology of KSHV, including the relationships between viral genotypic variation and the four clinicoepidemiologic forms of Kaposi's sarcoma, current viral detection methods and their utility, primary infection by KSHV, tissue culture and animal models of latent- and lytic-cycle gene expression and pathogenesis, and viral reactivation from latency. Recent advances in models of de novo endothelial infection, microarray analyses of the host response to infection, receptor identification, and cloning of full-length, infectious KSHV genomic DNA promise to reveal key molecular mechanisms of the candidate pathogeneic genes when expressed in the context of viral infection

show abstract

“…12,13,[16][17][18][19][20][21][22][23][24][25][26][27][28][29][30] In particular, PT-KS was primarily observed in kidney recipients ( Figure 1A), whereas lower PT-KS incidences have been recorded in patients receiving other SOTs, mainly liver and heart. PT-KS usually occurs rather early after transplantation (median interval, 30 months), usually as cutaneous or mucosal lesions, whereas visceral involvement occurs in 25%-50% of the cases.…”

Section: Posttransplantation Ks Pel and MCDmentioning

confidence: 99%

How I treat HHV8/KSHV-related diseases in posttransplant patients

Riva¹,

Luppi²,

Barozzi³

et al. 2012

Blood

View full text Add to dashboard Cite

Posttransplantation human herpesvirus-8 (HHV8)/Kaposi sarcoma herpesvirus (KSHV) primary infection and/or reactivations are associated with uncommon and sometimes fatal, neoplastic, and nonneoplastic diseases. HHV8-related clinical manifestations notably range from Kaposi sarcoma (KS) to either primary effusion lymphoma or multicentric Castleman disease B-cell malignancies, and from polyclonal HHV8-positive plasmacytic lymphoproliferative disorders to bone marrow failure and peripheral cytopenias, associated or not with hemophagocytic syndromes, and to acute hepatitis syndromes. We reviewed the patient series reported in the literature and summarized clinical management aspects, in terms of diagnosis, follow-up, and treatment. We described typical clinical presentations and histopathologic diagnostic features of these diseases, and we discussed the role of HHV8-specific serologic, molecular, and immunologic assays, particularly focusing on recent data from HHV8-specific T-cell monitoring in posttransplantation KS patients. We finally discussed actual therapeutic options, namely, the reduction or discontinuation of immunosuppressive therapy or the switch from calcineurin inhibitors to mTOR inhibitors, as alternatives to antineoplastic chemotherapy, along with the use of antiherpesvirus agents as prophylactic or therapeutic measures, and treatment with rituximab in posttransplantation multicentric Castleman disease patients and non-neoplastic HHV8-associated syndromes. IntroductionHerpesvirus-associated hematologic diseases often represent primary clinical challenges during the multidisciplinary follow-up of posttransplant patients, either with hematopoietic stem cell transplant (HSCT) or with solid organ transplant (SOT). In immunosuppressed organ recipients, latent human ␥-herpesvirus, namely, EBV and human herpesvirus-8 (HHV8)/Kaposi sarcoma herpesvirus (KSHV) are typically responsible for several virus-driven neoplastic proliferations, as well as they may sometimes cause uncommon, but equally life-threatening, non-neoplastic infectious complications. During the past decade, large amounts of experimental evidence have come out on these topics, and some of them have yet begun to influence the clinical behavior, in terms of diagnosis and treatment. Chiefly, EBV-related complications have been extensively studied and discussed, so that now physicians can rely on accurate and updated clinical recommendations, in particular dealing with early diagnosis, monitoring and treatment of EBV ϩ posttransplantation lymphoproliferative diseases (PTLDs). 1 With regards to HHV8, practical management of the virus-associated neoplastic lymphoproliferations has deeply been revised in HIVpositive subjects, 2,3 whereas in SOT and HSCT settings, the diagnostic and therapeutic issues about the various HHV8-driven manifestations (either neoplastic or non-neoplastic) are only occasionally reported in the literature, but most of these diseases revealed to be rapidly lethal if not timely recognized and adequately treated. Indeed, posttra...

show abstract

Kaposi's Sarcoma Associated with Previous Human Herpesvirus 8 Infection in Kidney Transplant Recipients

Cited by 96 publications

References 20 publications

Comparative Evaluation of Three Serological Methods for Detection of Human Herpesvirus 8-Specific Antibodies in Canadian Allogeneic Stem Cell Transplant Recipients

Comparative Evaluation of Three Serological Methods for Detection of Human Herpesvirus 8-Specific Antibodies in Canadian Allogeneic Stem Cell Transplant Recipients

Molecular Genetics of Kaposi's Sarcoma-Associated Herpesvirus (Human Herpesvirus 8) Epidemiology and Pathogenesis

How I treat HHV8/KSHV-related diseases in posttransplant patients

Contact Info

Product

Resources

About